Today's Stocks Driving Success For The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 91 points (0.6%) at 15,561 as of Thursday, July 18, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,136 issues advancing vs. 784 declining with 110 unchanged.

The Drugs industry currently sits up 5.9% versus the S&P 500, which is up 0.5%. Top gainers within the industry include Herbalife ( HLF), up 5.0%, and Alexion Pharmaceuticals ( ALXN), up 1.6%. On the negative front, top decliners within the industry include Biogen Idec ( BIIB), down 0.9%, and Bristol-Myers Squibb Company ( BMY), down 0.5%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Sanofi ( SNY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Sanofi is up $0.64 (1.2%) to $52.84 on light volume. Thus far, 384,814 shares of Sanofi exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $52.23-$52.96 after having opened the day at $52.31 as compared to the previous trading day's close of $52.20.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $139.2 billion and is part of the health care sector. Shares are up 10.2% year to date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Sanofi a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, AstraZeneca ( AZN) is up $0.42 (0.8%) to $50.29 on average volume. Thus far, 888,796 shares of AstraZeneca exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $50.12-$50.38 after having opened the day at $50.19 as compared to the previous trading day's close of $49.87.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $62.3 billion and is part of the health care sector. Shares are up 5.5% year to date as of the close of trading on Wednesday. Currently there is 1 analyst that rates AstraZeneca a buy, 2 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates AstraZeneca as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Get the full AstraZeneca Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, GlaxoSmithKline ( GSK) is up $0.29 (0.6%) to $52.44 on average volume. Thus far, 1.1 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $52.37-$52.72 after having opened the day at $52.70 as compared to the previous trading day's close of $52.15.

GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $127.5 billion and is part of the health care sector. Shares are up 20.0% year to date as of the close of trading on Wednesday. Currently there are 2 analysts that rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Actavis ( ACT) is up $2.50 (2.0%) to $124.58 on average volume. Thus far, 795,583 shares of Actavis exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $122.04-$125.32 after having opened the day at $122.08 as compared to the previous trading day's close of $122.08.

Actavis, Inc., an integrated specialty pharmaceutical company, engages in developing, manufacturing, marketing, selling, and distributing generic, branded generic, brand, biosimilar, and over-the-counter pharmaceutical products worldwide. Actavis has a market cap of $15.7 billion and is part of the health care sector. Shares are up 42.0% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Actavis a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Actavis as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Actavis Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $0.41 (0.7%) to $58.16 on light volume. Thus far, 4.2 million shares of Gilead exchanged hands as compared to its average daily volume of 11.4 million shares. The stock has ranged in price between $57.56-$58.44 after having opened the day at $57.85 as compared to the previous trading day's close of $57.75.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $87.2 billion and is part of the health care sector. Shares are up 55.6% year to date as of the close of trading on Wednesday. Currently there are 18 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, solid stock price performance, reasonable valuation levels and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec